Ovarian Serous Adenocarcinoma

P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Nov 2026

P2/3, N=582, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Dec 2026

We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Acquired drug resistance was linked to increased cyclin D1/E1 expression. This study confirms abnormal p16 IHC as a negative prognostic marker in LGSOC and establishes key determinants of sensitivity to CDK4/6 inhibitor-based therapy.

Overall, our results indicate that KIF26B is crucial for ovarian cancer progression and chemotherapy resistance, likely through SLC7A11 regulation. KIF26B may serve as a potential therapeutic target for overcoming paclitaxel resistance.

The presence of this eosinophilic cell population may help identify endometrial carcinomas harbouring BRAF mutations. Still, this association remains preliminary and merits confirmation in larger cohorts, ideally coupled with functional models.

This synchronous presentation underscores the importance of correlating imaging, cytology, extensive sampling, and immunohistochemistry to distinguish independent tumors from bilateral carcinoma. Accurate diagnosis enables appropriate oncologic management while avoiding overtreatment of benign lesions.

P1/2, N=27, Not yet recruiting, Auricula Biosciences Inc.

In 3D spheroids, both agents disrupted tumor architecture and reduced viability, alone or in combination with carboplatin. Our findings highlight that platinum resistance in HGSOC can be tackled by repurposing MEF and MPA that act also as AKR1C inhibitors.

This case underscores the need for clinical awareness of post-vaccination immunologic phenomena that may mimic plasma cell neoplasm. Recognition of such transient aberrancies can prevent unnecessary invasive investigations and broaden understanding of vaccine-induced immune dynamics.

Despite these advances, major challenges persist, including intratumoural heterogeneity and the poor diversity of genomic datasets. Artificial Intelligence (AI) technology, Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing, neoantigen-guided immunotherapy and ovarian cancer vaccination indicate a promising future for genomics-guided interventions and support the integration of genomics within multi-omic approaches to improve HGSOC outcomes.

Of two patients with the HER2-ultralow phenotype, one was alive with no evidence of disease at 16 months follow-up. The results support the idea that HER2/neu overexpression is exceptionally rare in LGSOC; nevertheless, future trials are essential to fully characterize the spectrum of HER2/neu alterations in LGSOC and to determine definitively whether the rare cases with mutations or ultralow expression could represent a small subgroup that might benefit from specific targeted agents.